drugset
drugset / Trial / NCT00546000

Cutivate Lotion HPA Axis Pediatric Study

NCT00546000 ↗

Phase 4 Completed 56 enrolled Fougera Pharmaceuticals Inc.
NaSingle-groupOpen-labelTreatment

Summary

A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.

Timeline

Start
2007-07
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 0.05 % —

Indications

atopic eczema